ID   KMS-34/Cfz
AC   CVCL_IQ85
DR   cancercelllines; CVCL_IQ85
DR   GEO; GSM1692590
DR   GEO; GSM1692591
DR   GEO; GSM1692592
DR   Wikidata; Q54900183
RX   PubMed=26109433;
CC   Population: Japanese.
CC   Characteristics: Produces IgA kappa.
CC   Selected for resistance to: ChEBI; CHEBI:65347; Carfilzomib (Kyprolis; PX-171-007).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2996 ! KMS-34
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 10
//
RX   PubMed=26109433; DOI=10.18632/oncotarget.4530;
RA   Riz I., Hawley T.S., Hawley R.G.;
RT   "KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to
RT   carfilzomib resistance in multiple myeloma models.";
RL   Oncotarget 6:14814-14831(2015).
//